April 8, 2024 in Kineta Press Release

Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical Trial

  Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts Favorable clinical safety and tolerability profile observed with ...

Read More
January 17, 2024 in Kineta Press Release

Kineta Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors

  Cleared First Four Monotherapy Doses and Initial Combination Cohort with No Dose Limiting Toxicities at any Dose Level KVA12123 Monotherapy Demonstrated Dose Proportional Induction of Pro-inf ...

Read More
December 13, 2023 in Kineta Press Release

Kineta Publishes Preclinical Data Demonstrating the Potential of Anti-VISTA Antibody KVA12123 as an Immunomodulatory Therapy for Cancer

  VISTA Blocking KVA12123 Monoclonal Antibody (mAb) Engineered to Provide Strong Single Agent Anti-Tumor Activity While Minimizing Cytokine Related Adverse Events KVA12123 recognizes a unique V ...

Read More
October 5, 2023 in Kineta Press Release

Kineta, Inc. Announces Closing of $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

  SEATTLE, Oct. 05, 2023 -- Kineta, Inc. (Nasdaq: KA) (the "Company" or "Kineta"), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that add ...

Read More
October 4, 2023 in Kineta Press Release

Kineta Presents New Preclinical Data on Lead Anti-CD27 Agonist Antibody at AACR Special Conference on Tumor Immunology and Immunotherapy

Preclinical data highlights CD27's mechanism of action and strong anti-tumor activity as a monotherapy and in combination with other checkpoint inhibitors   SEATTLE, Oct. 04, 2023 -- Kineta ...

Read More